14 results about "E2 prostaglandin" patented technology

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The invention belongs to the technical field of drug delivery and tumor immunotherapy, and particularly relates to an oncolytic virus vesicle as well as a preparation method and application thereof. The preparation method comprises the following steps: co-incubating oncolytic adenovirus and platelets in a buffer system containing prostaglandin E2, and inducing to form an inner membrane encapsulation body; and activating and releasing the vesicles under the conditions of 36-38 DEG C and 4-6% CO2, and carrying out gradient centrifugal collection of 300g, 2000g, 10000g and 100000g. The particle size of the oncolytic virus-loaded vesicle is 50-200nm, the surface of the oncolytic virus-loaded vesicle contains CD41, CD61 and P-selectin, and the oncolytic virus-loaded vesicle can realize long circulation and lung targeting delivery of oncolytic viruses, is suitable for preparing drugs for treating breast cancer and breast cancer lung metastasis, and has a remarkable tumor inhibition effect.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The invention relates to the technical field of microorganisms, and particularly discloses lactobacillus acidophilus PIS4 capable of improving dysmenorrhea and application of the lactobacillus acidophilus PIS4. The lactobacillus acidophilus PIS4 is separated from genital tracts of healthy women, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34554, and the preservation date is May 15, 2025. The lactobacillus acidophilus PIS4 is used for preparing the lactobacillus acidophilus PIS4. The lactobacillus acidophilus strain PIS4 provided by the invention is proved to be capable of inhibiting the gene expression of prostaglandin E synthase 2 (pges-2) and reducing the synthesis of prostaglandin E2 and prostaglandin F2alpha, and has effective relieving and improving effects on primary dysmenorrhea.

The invention belongs to the technical field of biomedicine, and relates to a culture medium for human placenta organoid in early pregnancy as well as preparation and application of the culture medium. The culture medium is prepared from DMEM / F12, and an N-2 additive is added into the culture medium; a B-27 additive; primary cell antibiotics; and N, N-acetyl-L-cysteine; l, L-glutamine; recombinant human epidermal growth factors; cHIR99021, CHIR99021; a recombinant human R-spinal protein 1; recombining a human fibroblast growth factor; recombinant human hepatocyte growth factors; a83-01, A83-01; prostaglandin E2; y-27632, Y-27632; and fetal bovine serum albumin. By improving the components of the culture medium of the human placenta organoid, the obtained human placenta organoid is better in growth state and balling rate, the apoptosis of the organoid is reduced, and a foundation is laid for further application to research of downstream molecular biology and cytobiology.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

The invention belongs to the field of biological medicines, and particularly relates to a novel application of forsythin in preparation of a medicine for preventing and treating amyotrophy. In-vivo and in-vitro experiments prove that the phillyrin can remarkably improve the level of endogenous prostaglandin E2 by inhibiting the activity or expression of 15-hydroxyprostaglandin dehydrogenase in muscular tissues, so that the expression of muscular atrophy key factors FOXO3a and Atrogin-1 is inhibited, and finally the effects of protecting muscle quality and improving muscle functions are achieved. The invention reveals that forsythin has the functions of inhibiting 15-PGDH and relieving muscle atrophy for the first time, and brand new medical application is provided for forsythin. The invention provides a brand-new therapeutic scheme and pharmaceutical composition for treating sarcopenia by using forsythin as an active component and regulating the 15-PGDH / PGE2 pathway. The invention provides an important candidate compound for developing efficient and safe sarcopenia resisting medicines, and has important practical significance.

The invention belongs to the technical field of animal breeding. More specifically, the invention relates to a method for predicting ewe embryo transplantation pregnancy results. The research finds that luteinizing hormone, cortisol and prostaglandin E2 in the estrus period of the ewe have significant correlation with the pregnancy result after the ewe embryo transplantation in a specific concentration range for the first time, and ROC curve analysis proves that the three can be used as biomarkers for predicting the pregnancy result after the ewe embryo transplantation. On the basis, the invention provides a method for predicting the pregnancy result of ewe embryo transplantation, and the pregnancy result is predicted according to the concentration of the reproductive hormone by detecting the concentration of the reproductive hormone in the peripheral blood of the receptor ewe in the estrus period. According to the method, pregnancy potential evaluation can be realized before transplantation, and the prediction timeliness is remarkably improved. In addition, breeding managers can screen high-pregnancy-potential individuals accordingly, and breeding efficiency is improved. The hormone abuse condition in embryo transplantation is reduced, the culture cost is reduced, and the method has good application prospects and value.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The application discloses a polyketone compound, a preparation method thereof and application of the polyketone compound in Cox2 enzyme inhibition and anti-inflammatory drugs, and has the characteristics that the structural formula of the compound is shown as I, the preparation method steps include obtaining a fermentation product containing the polyketone compound through fermentation culture of a strain, then soaking the fermentation product with ethyl acetate to obtain a crude extract, and on the basis, obtaining the crude extract through normal-phase silica gel column chromatography, reverse-phase medium-pressure column chromatography and semi-preparative high performance liquid chromatography separation and purification, and the polyketone compound has obvious anti-inflammatory activity; and the polyketone compound can significantly inhibit the generation of nitric oxide, active oxygen and prostaglandin E2 and inhibit COX-2 enzyme activity, and is expected to become an active drug molecule for inflammation treatment.

The application provides a prostate cancer organoid special culture medium and a culture method thereof, and belongs to the technical field of biological medicine. The prostate cancer organoid special culture medium is composed of a basic culture medium and a culture additive. The basic culture medium does not contain exogenous added Noggin recombinant protein and R-spondin recombinant protein. The culture additive comprises basic fibroblast growth factor, keratinocyte growth factor, fibroblast growth factor 10, insulin, p38MAPK signal pathway inhibitor, insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, forskolin and androgen. The prostate cancer organoid special culture medium can reduce the cost and improve the culture success rate.

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

The invention relates to the technical field of oral care ingredients, and discloses a preparation method of a chamomilla recutita flower extract and an oral care composition containing the chamomilla recutita flower extract, the chamomilla recutita flower extract is obtained by soaking chamomilla recutita flower growing in mediterranean climate in 1, 2-propylene glycol and water, draining water, pressurizing and filtering; the oral care composition comprises the following components: a chamomilla recutita flower extract, sodium monofluorophosphate and water. The chamomilla recutita flower extract capable of effectively inhibiting expression of inflammatory factor prostaglandin E2 (PGE2) and inhibiting growth of porphyromonas gingivalis and streptococcus mutans is screened and compounded with sodium monofluorophosphate to form the oral care composition, and the oral care composition has good effects of inhibiting bacteria, relieving gingivitis and relieving halitosis.